BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 05:15:02 01/07/2024 pm IST | ||
| 995.5 EUR | -0.07% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 995.5 | -0.07% |
| 28/24/28 | 996.2 | +0.48% |
| 27/24/27 | 991.5 | +0.28% |
| 26/24/26 | 988.8 | -0.30% |
| 25/24/25 | 991.8 | +0.31% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 05:15 pm IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD61MT |
| ISIN | DE000HD61MT1 |
| Date issued | 31/05/2024 |
| Strike | 1,050 $ |
| Maturity | 21/03/2025 (263 Days) |
| Parity | 1 : 1 |
| Emission price | 940.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 996.5 € |
|---|---|
| Lowest since issue | 940 € |
| Spread | 1.07 € |
| Spread % | 0.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
